Clinical Trial Update: EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases [Phase 1, Phase 2]

View source ↗

Summary

This document provides an update on an early-stage study of EBV-Tscm cytotoxic T cells for Epstein-Barr virus–driven lymphomas and post-transplant lymphoprolife…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Associated Lymphoma
• Post-transplant Lymphoproliferative Disorder

Drugs mentioned

• EBV-Tscm Cytotoxic T Cells (EBV-Tscm CTLs)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: EBV Lymphoma, Post-transplant Lymphoproliferative Disease (PTLD) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING